EXHIBIT 20.1


DATE:    April 26, 2001

CONTACT: John Hupp, Director
         (952) 820-0022

SYMBOL:  DEVT.OB

RE:      Developed Technology Resource, Inc.



                              FOR IMMEDIATE RELEASE
                              ---------------------


         MINNEAPOLIS, MINNESOTA - Developed Technology Resource, Inc. (the
"Company") announced today that it is declaring a stock dividend to its
shareholders of record as of 4:30 p.m. central daylight savings time, on May 7,
2001. The dividend will consist of one share of the common stock of its wholly
owned subsidiary, DTR-Med Pharma Corp., for each share of the Company held of
record at the record date. The payment date for the dividend is set at May 15,
2001.

         DTR-Med Pharma Corp. holds an indirect royalty interest in medical
technology which is designed to permit the measurement, through a pressure
sensitive system, of the elasticity and hardness of soft tissue. Through
digitization, a clinician using this system is able to generate an image showing
the size and location of nodules in human tissue, as an aid to cancer detection.
DTR-Med Pharma Corp.'s royalty interest has been determined to have a fair
market value of approximately $107,000.

         It was also announced that the Company and DTR-Med Pharma Corp. entered
into a





Stock Exchange Agreement with the shareholders of Pro-Pharmaceuticals, Inc.,
based in Newton, Massachusetts, whereby DTR-Med Pharma Corp. will issue
12,354,670 shares of its common stock in exchange for all of the outstanding
shares of common stock of Pro-Pharmaceuticals, Inc. Pro-Pharmaceuticals, Inc. is
in the process of developing what is believed to be an improved drug delivery
system that reduces toxicity and increases the effectiveness of drugs currently
in use for treatment of various diseases including cancer.

         The closing of the transaction with the shareholders of
Pro-Pharmaceuticals, Inc. is expected to occur in mid-May 2001. Following the
closing, DTR-Med Pharma Corp. will have approximately 13,576,560 shares of
common stock outstanding, approximately 1,221,890 of which will be held by the
Company's shareholders as a result of the stock dividend. In addition, following
the closing, it is anticipated that from approximately 1,150,000 to 3,500,000
additional shares of DTR-Med Pharma Corp. will be issued in connection with the
incurrence of approximately $1,200,000 in debt, and the conversion of that debt
into DTR-Med Pharma Corp. common stock.

         The common stock of the Company is traded on the NASDAQ Bulletin Board
under the symbol DEVT.OB. DTR-Med Pharma Corp.'s common stock is restricted by
its Articles of Incorporation, which provide that its outstanding stock may not
be sold, transferred or assigned without written approval of DTR Med-Pharma
Corp. until the earlier of May 1, 2003 or the 90th day following the date its
common stock is registered under the Securities Exchange Act of 1934. DTR-Med
Pharma, to be renamed "Pro-Pharmaceuticals, Inc.," expects to register its
common stock under the Securities Exchange Act of 1934. It is contemplated that
such





registration will occur in mid-Summer 2001.

         This release contains forward looking information, including statements
regarding a general description of certain technology, the closing of a
transaction by the Company with the shareholders of Pro-Pharmaceuticals, Inc.,
and the registration of the common stock of DTR-Med Pharma Corp. under the
Securities Exchange Act of 1934. These forward looking statements are based on
the Company's current expectations, and there is no assurance that the results
contained in these statements will occur, of that the technology discussed will
have any future value.

                                     # # # #